SCHEMBL6704375

SCHEMBL6704375

Cc1ccc(N)cc1C1CCOC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
CASP1 P29466 4/20 0.38
CYP3A4 P08684 2/20 0.36
TSHR P16473 2/20 0.36
RAF1 P04049 2/20 0.35
BRAF P15056 1/20 0.35
RECQL P46063 1/20 0.35
ASH1L Q9NR48 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA4 P43681 1/20 0.34
F2 P00734 1/20 0.33
PLG P00747 1/20 0.33
PLAU P00749 1/20 0.33
PLAT P00750 1/20 0.33
KLK1 P06870 1/20 0.33
PRSS1 P07477 1/20 0.33
KDM4E B2RXH2 3/20 0.33
GAA P10253 2/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18031194 0.80 ALDH1A1 (0.50) ALDH1A1CASP1CYP3A4TSHRRECQL
SCHEMBL25800133 0.78 ALDH1A1 (0.39) ALDH1A1
SCHEMBL20242087 0.76 F2 (0.44) ALDH1A1TSHRF2PLGPLAU
SCHEMBL14320620 0.76 OPRL1 (0.43) ALDH1A1CASP1CYP3A4TSHRRAF1
Hydrochloric Acid SCHEMBL31406372 0.75 ALDH1A1 (0.45) ALDH1A1CASP1CYP3A4TSHRRECQL
SCHEMBL28452283 0.75 HTR2C (0.52) PDE10A
SCHEMBL28455605 0.74 ALDH1A1 (0.37) ALDH1A1CASP1CYP3A4TSHRRAF1
SCHEMBL24722951 0.74 SLC6A4 (0.37) CHRNB2CHRNA4F2PLGPLAU
SCHEMBL2486113 0.74 TSHR (0.35) ALDH1A1TSHRGAACA12CA1
SCHEMBL1714160 0.74 TSHR (0.35) ALDH1A1TSHRGAACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120288501-A1 SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) 2012-11-15 US disclosed
US-20120288501-A1 SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) 2012-11-15 US disclosed
US-20120288501-A1 SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) 2012-11-15 US disclosed
US-8299108-B2 for treatment of hematological/hormone-dependent cancer NOVARTIS AG (CH) 2012-10-30 US disclosed
US-8299108-B2 for treatment of hematological/hormone-dependent cancer NOVARTIS AG (CH) 2012-10-30 US disclosed
US-8299108-B2 for treatment of hematological/hormone-dependent cancer NOVARTIS AG (CH) 2012-10-30 US disclosed
US-20040122237-A1 Substituted benzazoles and methods of their use as inhibitors of Raf kinase NOVARTIS AG (CH) 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122237-A1 Substituted benzazoles and methods of their use as inhibitors of Raf kinase BRAF, RAF1, ARAF ALDH1A1 1216/4885CASP1 2059/4885CYP3A4 1457/4885
US-20120288501-A1 SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE BRAF, RAF1, ARAF ALDH1A1 1216/4885CASP1 2059/4885CYP3A4 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.